Lymphangiogenomics

 

 
Basel                        Braunschweig               Brussels              Gothenborg               Heidelberg                Helsinki                   Kuopio                     Leuven                   Milano                      Paris                  Stockholm                 Vienna                      Uppsala
Basel       Braunschweig       Brussels      Goteborg      Heidelberg      Helsinki      Kuopio      Leuven      Milano      Paris      Stockholm      Vienna      Uppsala    
   

Home ●

 

Member Area ●

 

 

 

TARGETED TREATMENT FOR LYMPHATIC DISEASES

 

 

Work Packages ●

 

Consortium Partners ●

   

New Publication ●

    

Press Release ●

 

Meetings ●

 

Links ●

 

Jobs ●

  

EU Genomic News ●

 

Lymphangiogenomics
database ●

 

Impressum / Contact ●

 

 

Last Update: February 18, 2008

 

  

 

 

 

  

 

 

 

Lymphatix performes clinical investigation on VEGF-C therapy for lymphedema and will develop new therapies that modulate growth and function of lymphatic vessels.

 

 

Person in response:

 

 

Mr. Timo Vaara, CEO

Lymphatix Oy (Lymphatix Ltd)

Biomedicum 2

Tukholmankatu 8B

FIN-00290 Helsinki

Phone: +358 40 8327 090

Fax: +358 9 68420130

E-mail: timo.vaara(at)lymphatix.fi